000			01820 a2200517 4500
005			20250516055703.0
264		0	_c20120127
008			201201s 0 0 eng d
022			_a1529-0131
024	7		_a10.1002/art.30634 _2doi
040			_aNLM _beng _cNLM
100	1		_aAletaha, Daniel
245	0	0	_aJoint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. _h[electronic resource]
260			_bArthritis and rheumatism _cDec 2011
300			_a3702-11 p. _bdigital
500			_aPublication Type: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdalimumab
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntibodies, Monoclonal _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal, Humanized _xtherapeutic use
650	0	4	_aAntirheumatic Agents _xtherapeutic use
650	0	4	_aArthritis, Rheumatoid _xdrug therapy
650	0	4	_aArthrography
650	0	4	_aDisease Progression
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Therapy, Combination
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aInfliximab
650	0	4	_aJoints _xpathology
650	0	4	_aMale
650	0	4	_aMethotrexate _xtherapeutic use
650	0	4	_aMiddle Aged
650	0	4	_aOutcome Assessment, Health Care _xmethods
650	0	4	_aRemission Induction
650	0	4	_aRetrospective Studies
650	0	4	_aSeverity of Illness Index
650	0	4	_aTreatment Outcome
650	0	4	_aYoung Adult
700	1		_aSmolen, Josef S
773	0		_tArthritis and rheumatism _gvol. 63 _gno. 12 _gp. 3702-11
856	4	0	_uhttps://doi.org/10.1002/art.30634 _zAvailable from publisher's website
999			_c21190292 _d21190292